Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis

PLoS Genetics

Volumn 13, Issue 7, 2017, Pages

  Dietrich, Paula ^a   Johnson, Irudayam Maria ^a   Alli, Shanta ^a   Dragatsis, Ioannis ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; IRON; RNA 18S;

ADULT; ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN CALCIFICATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GLIOSIS; HOMEOSTASIS; HTT GENE; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; THALAMUS; ANIMAL; BRAIN; BRAIN DISEASE; C57BL MOUSE; CALCINOSIS; DISEASE MODEL; EXON; GENE EXPRESSION REGULATION; GENETICS; GENOTYPING TECHNIQUE; HUNTINGTON CHOREA; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN DISEASES; CALCINOSIS; DISEASE MODELS, ANIMAL; EXONS; FEMALE; GENE EXPRESSION REGULATION; GENOTYPING TECHNIQUES; GLIOSIS; HOMEOSTASIS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; IRON; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, RIBOSOMAL, 18S;

EID: 85026661643     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006846     Document Type: Article

References (78)

1. Walker FO, Huntington’s disease. Lancet. 2007;369(9557): 218–228. doi: 10.1016/S0140-6736(07)60111-1 17240289
2. Reiner A, Dragatsis I, Dietrich P, Genetics and neuropathology of Huntington’s disease. Int Rev Neurobiol. 2011;98: 325–372. doi: 10.1016/B978-0-12-381328-2.00014-6 21907094
3. Ortega Z, Lucas JJ, Ubiquitin-proteasome system involvement in Huntington’s disease. Front Mol Neurosci. 2014;7: 77. doi: 10.3389/fnmol.2014.00077 25324717
4. Yamada M, Tsuji S, Takahashi H, Pathology of CAG repeat diseases. Neuropathology. 2000;20(4): 319–325. 11211058
5. Hickey MA, Chesselet MF, Apoptosis in Huntington’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(2): 255–265. doi: 10.1016/S0278-5846(03)00021-6 12657365
6. Shannon KM, Fraint A, Therapeutic advances in Huntington’s Disease. Mov Disord. 2015;30(11): 1539–1546. doi: 10.1002/mds.26331 26226924
7. Zhang Y, Friedlander RM, Using non-coding small RNAs to develop therapies for Huntington’s disease. Gene Ther. 2011;18(12): 1139–1149. doi: 10.1038/gt.2011.170 22158031
8. Wild EJ, Tabrizi SJ, Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?Mov Disord. 2014;29(11): 1434–1445. doi: 10.1002/mds.26007 25155142
9. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol. 2009;65(3): 276–285. doi: 10.1002/ana.21569 19334076
10. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009; 17(6): 1053–1063. doi: 10.1038/mt.2009.17 19240687
11. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther. 2011;19(12): 2152–2162. doi: 10.1038/mt.2011.219 22031240
12. Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(Pt4): 1197–1209.
13. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S, Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 2001;24(3): 182–188. 11182459
14. Dietrich P, Dragatsis I, LeDoux M, Use of Genetically engineered mice to study the biology of huntingtin. In: Movement Disorders: Genetics and Models, 2nd ed. San Diego: Elsevier Academic Press; 2015. pp. 547–555.
15. Saudou F, Humbert S, The Biology of Huntingtin. Neuron. 2016;89(5): 910–926. doi: 10.1016/j.neuron.2016.02.003 26938440
16. Dragatsis I, Levine MS, Zeitlin S, Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000;26(3): 300–306. doi: 10.1038/81593 11062468
17. Barnat M, Le Friec J, Benstaali C, Humbert S, Huntingtin-mediated multipolar-bipolar transition of newborn cortical neurons is critical for their postnatal neuronal morphology. Neuron. 2017; 93(1): 99–114. doi: 10.1016/j.neuron.2016.11.035 28017473
18. Hayashi S, McMahon AP, Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244(2): 305–318. doi: 10.1006/dbio.2002.0597 11944939
19. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A, Increased apoptosis and early embryonic leathlity in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet. 1995;11(2): 155–163. doi: 10.1038/ng1095-155 7550343
20. Glynn D, Bortnick RA, Morton AJ, Complexin II is essential for normal neurological function in mice. Hum Mol Genet. 2003;12(19): 2431–2448. doi: 10.1093/hmg/ddg249 12915444
21. Taradach C, Greaves P, Spontaneous eye lesions in laboratory animals: incidence in relation to age. Crit Rev Toxicol. 1984;12(2): 121–147. doi: 10.3109/10408448409023759 6368130
22. Hosokawa M, Takeshita S, Higuchi K, Shimizu K, Irino M, Toda K, et al. Cataract and other ophthalmic lesions in senescence accelerated mouse (SAM). Morphology and Incidence of senescence associated ophthalmic changes in mice. Exp Eye Res. 1984;38(2): 105–114. 6714329
23. Yan J, Zhang H, Liu Y, Zhao F, Zhu S, Xie C, et al. Germline deletion of huntingtin causes male infertility and arrested spermiogenesis in mice. J Cell Sci. 2016;129(3): 492–501. doi: 10.1242/jcs.173666 26659666
24. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, Kim J, et al. Expression of normal and mutant huntingtin in the developing brain. J Neurosci. 1996;16(17): 5523–5535. 8757264
25. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, et al. Huntingtin localization in brains of normal and Huntington’s disease patients. Ann Neurol. 1997;42(4): 604–612. doi: 10.1002/ana.410420411 9382472
26. Kelly CM, Dunnett SB, Rosser AE, Medium spiny neurons for transplantation in Huntington’s disease. Biochem Soc Trans. 2009;37(Pt1): 323–328.
27. Abate EG, Clarke BL, Review of hypoparathyroidism. Front Endocrinol (Lausanne). 2017; 7:172.
28. Ha CM, Park S, Choi YK, Jeong JY, Oh CJ, Bae KH, et al. Activation of Nrf2 by dimethyl fumarate improves vascular calcification. Vascul Pharmacol. 2014;63(1):29–36. doi: 10.1016/j.vph.2014.06.007 25135648
29. Leibrock CB, Alesutan I, Voelkl J, Michael D, Castor T, Kohlhofer U, et al. Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice. J Mol Med (Berl). 2016;94(1):95–106.
30. Paloian NJ, Leaf EM, Giachelli CM, Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification. Kidney Int. 2016;89(5):1027–1036. doi: 10.1016/j.kint.2015.12.046 27083280
31. Babbitt DP, Tang T, Dobbs J, Berk R, Idiopathic familial cerebrovascular ferrocalcinosis (Fahr’s disease) and review of differential diagnosis of intracranial calcification in children. Am J Roentgenol Radium Ther Nucl Med. 1969;105(2): 352–358. 4179335
32. Beall SS, Patten BM, Mallette JL, Jankovic J, Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. Ann Neurol. 1989;26(4): 569–575. doi: 10.1002/ana.410260412 2817830
33. Manyam BV, What is and is not Fahr’s disease. Parkinsonism Relat Disord. 2005;11(2): 73–80. doi: 10.1016/j.parkreldis.2004.12.001 15734663
34. Acou M, Vanslembrouck J, Deblaere K, Bauters W, Achten E, Fahr disease. JBR-BTR. 2008; 91(1): 19. 18447126
35. Kıroğlu Y, Callı C, Karabulut N, Oncel C, Intracranial calcifications on CT. Diagn Interv Radiol. 2010;16(4): 263–269. doi: 10.4261/1305-3825.DIR.2626-09.1 20027545
36. Dragatsis I, Efstratiadis A, Zeitlin S, Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development. 1998;125(8): 1529–1539. 9502734
37. Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI, Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet. 2007;16(16): 1905–1920. doi: 10.1093/hmg/ddm138 17567778
38. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME, Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet. 2000;9(19): 2789–2797. 11092755
39. Zheng W, Monnot AD, Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther. 2012;133(2): 177–188. doi: 10.1016/j.pharmthera.2011.10.006 22115751
40. Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D, et al. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal. 2014;20(8): 1324–1363. doi: 10.1089/ars.2012.4931 23815406
41. Lawen A, Lane DJ, Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal. 2013;18(18):2473–5207. doi: 10.1089/ars.2011.4271 23199217
42. Wallace DF, The regulation of iron absorbtion and homeostasis. Clin Biochem Rev. 2016;37(2):51–62. 28303071
43. Wang G, Liu X, Gaertig MA, Li S, Li XJ, Ablation of huntingtin in adult neurons is non-deleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113(12): 3359–3364. doi: 10.1073/pnas.1524575113 26951659
44. Pla P, Orvoen S, Benstaali C, Dodier S, Gardier AM, David DJ, et al. Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse. PLoS One. 2013;8(9): e73902. doi: 10.1371/journal.pone.0073902 24019939
45. Brannan TS, Burger AA, Chaudhary MY, Bilateral basal ganglia calcifications visualized on CT scan. J Neurol Neurosurg Psychiatry. 1980;43(5): 403–406. 7420090
46. Wisniewski KE, French JH, Rosen JF, Kozlowski PB, Tenner M, Wisniewski HM, Basal ganglia calcification (BGC) in Down’s syndrome (DS)—another manifestation of premature aging. Ann N Y Acad Sci. 1982;396: 179–189. 6185033
47. Casanova MF, Araque JM, Mineralization of the basal ganglia: implications for neuropsychiatry, pathology and neuroimaging. Psychiatry Res. 2003;121(1): 59–87. 14572624
48. Fraser H, Bilateral thalamic calcification in ageing mice. J Pathol Bacteriol. 1968;96(1): 220–222. doi: 10.1002/path.1700960124 5691245
49. Sheldon WG, Greenman DL, Spontaneous lesions in control and BALB/C female mice. J Environ Pathol Toxicol. 1980;3(3 Spec No): 155–167. 7365377
50. Morgan KT, Johnson BP, Frith CH, Townsend J, An ultrastructural study of spontaneous mineralization in the brains of aging mice. Acta Neuropathol. 1982;58(2): 120–124. 7180386
51. Kalueff A, Loseva E, Haapasalo H, Rantala I, Keranen J, Lou YR, et al. Thalamic calcification in vitamin D receptor knockout mice. Neuroreport. 2006;17(7): 717–721. doi: 10.1097/01.wnr.0000215770.79281.e4 16641675
52. Oliveira JR, Spiteri E, Sobrido MJ, Hopfer S, Klepper J, Voit T, et al. Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology. 2004;63(11): 2165–2167. 15596772
53. Lemos RR, Ramos EM, Legati A, Nicolas G, Jenkinson EM, Livingston JH, et al. Update and mutational analysys of Slc20a2: a major cause of primary familial brain calcification. Hum. Mutat. 2015;36(5): 489–495. doi: 10.1002/humu.22778 25726928
54. Jensen N, Schrøder HD, Hejbøl EK, Füchtbauer EM, de Oliveira JR, Pedersen L, Loss of function of Slc20a2 associated with familial idiopathic basal ganglia calcification in humans causes brain calcifications in mice. J Mol Neurosci. 2013;51(3): 994–949. doi: 10.1007/s12031-013-0085-6 23934451
55. Nicolas G, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology. 2013;80(2): 181–187. doi: 10.1212/WNL.0b013e31827ccf34 23255827
56. Keller A, Westenberger A, Sobrido MJ, García-Murias M, Domingo A, Sears RL, et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet. 2013;45(9): 1077–1082. doi: 10.1038/ng.2723 23913003
57. Smith Y, Galvan A, Ellender TJ, Doig N, Villalba RM, Huerta-Ocampo I, et al. The thalamostriatal system in normal and diseased states. Front Syst Neurosci. 2014;8:5. doi: 10.3389/fnsys.2014.00005 24523677
58. Arbuthnott GW, Thalamostriatal synapses-another substrate for dopamine action?Prog Brain Res. 2014;211:1–11. doi: 10.1016/B978-0-444-63425-2.00001-5 24968774
59. Connor JR, Menzies SL, Burdo JR, Boyer PJ, Iron and iron management proteins in neurobiology. Pediatr Neurol. 2001;25(2): 118–129. 11551742
60. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001;27(2): 209–214. doi: 10.1038/84859 11175792
61. Jeong SY, Crooks DR, Wilson-Ollivierre H, Ghosh MC, Sougrat R, Lee J, et al. Iron insufficiency compromises motor neurons and their mitochondrial function in Irp2-null mice. PLoS One. 2011;6(10): e25404. doi: 10.1371/journal.pone.0025404 22003390
62. Li X, Sapp E, Valencia A, Kegel KB, Qin ZH, Alexander J, et al. A function of huntingtin in the guanine nucleotide exchange of Rab11. Neuroreport. 2008;19(16):1643–1647. doi: 10.1097/WNR.0b013e328315cd4c 18845944
63. Power D, Srinivasan S, Gunawardena S, In-vivo evidence for the disruption of Rab11 vesicle transport by loss of huntingtin. Neuroreport. 2012;23(16):970–977. doi: 10.1097/WNR.0b013e328359d990 23032403
64. Wilcke M, Johannes L, Galli T, Mayau V, Goud B, Salamero J, Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-golgi network. J Cell Biol. 2000;151(6):1207–1220. 11121436
65. Kobayashi H, Fukuda M, Arf6, Rab11 and transferrin receptor define distinct populations of recycling endosomes. Commun Integr Biol. 2013; 6(5): e25036. doi: 10.4161/cib.25036 24255739
66. Lin Q, Feng J, Zhao X, Zhang G, Wang W, Expression and function of ferroportin in O-2A progenitor cells. Anat Rec. (Hoboken). 2013;296(1): 108–116.
67. Sangokoya C, Doss JF, Chi JT, Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet. 2013;9(4): e1003408. doi: 10.1371/journal.pgen.1003408 23593016
68. Zhang Y, Engelman J, Friedlander RM, Allele-specific silencing of mutant Huntington’s disease gene. J Neurochem. 2009;108(1): 82–90. doi: 10.1111/j.1471-4159.2008.05734.x 19094060
69. Kay C, Skotte NH, Southwell AL, Hayden MR, Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1): 29–36. doi: 10.1111/cge.12385 24646433
70. Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22(12): 2093–2106. doi: 10.1038/mt.2014.153 25101598
71. Monteys AM, Wilson MJ, Boudreau RL, Spengler RM, Davidson BL, Artificial mRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. Mol Ther Nucleic Acids. 2015;4: e234. doi: 10.1038/mtna.2015.7 25849618
72. Dragatsis I, Zeitlin S, Dietrich P, Huntingtin-associated protein 1 (Hap1) mutant mice bypassing the early postnatal lethality are neuroanatomically normal and fertile but display growth retardation. Hum Mol Genet. 2004;13(24): 3115–3125. doi: 10.1093/hmg/ddh328 15496430
73. Dietrich P, Shanmugasundaram R, Shuyu E, Dragatsis I, Congenital hydrocephalus associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 lineages. Hum Mol Genet. 2009;18(1): 142–150. doi: 10.1093/hmg/ddn324 18838463
74. Macdonald D, Tessari MA, Boogaard I, Smith M, Pulli K, Szynol A, et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins. PLoS One. 2014;9(5): e96854. doi: 10.1371/journal.pone.0096854 24816435
75. Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP, The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington’s disease mice. Neurobiol Dis. 2012;47(1): 75–91. doi: 10.1016/j.nbd.2012.03.025 22472187
76. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ, Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci. 2003;23(6): 2193–2202. 12657678
77. Sands SA, Leung-Toung R, Wang Y, Connelly J, LeVine SM, Enhanced histochemical detection of iron in paraffin sections of mouse central nervous system tissue: application in the APP/PS1 mouse model of Alzheimer’s disease. ASN Neuro. 2016;8(5).
78. Grishchuk Y, Peña KA, Coblentz J, King VE, Humphrey DM, Wang SL, et al. Impaired myelination and reduced brain ferric iron in the mouse model of mucolipidosis IV. Dis Model Mech. 2015;8(12): 1591–1601. doi: 10.1242/dmm.021154 26398942